Resources
- BNET Author Biography
Jim Edwards, a former managing editor of Adweek, has covered drug marketing at Brandweek for four years. He is a former Knight-Bagehot fellow at Columbia University's business and journalism schools. He has also won the Neal award for business journalism, an S.P.J. award for investigative journalism, and the N.J. Press...- more about Jim Edwards »
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- What’s Inside That FTC Report on Junk Food Marketing?
- The FTC detailed this week how much money is spent marketing junk food to kids. Most stories, like this one in the New York Times, went with the headline number: $1.6 billion. But the full report is more than 100 pages long, and filled with scary hidden...
- Blog posts 2008-07-31
- Weight-Loss Drugs -- Big Pharma’s Elusive El Dorado
- With America’s obesity problem getting worse by the day, there's plenty of money to be made fighting fat with new drugs. So why do weight-loss pills keep going down in flames? by Jim Edwards
- Blog posts 2008-07-30
- FDA Probes Shine Harsh Light on Pharma Biz
- It must be awful to work at the FDA right now. There you are, sitting in your cubicle, trying to make sure the pharmaceutical industry cures more people than it kills. But every five minutes some investigator from the Government Accountability Office calls you into the conference room for a...
- Blog posts 2008-07-31
- Should We Be Surprised That Schering-Plough Execs Are "Surprised" By Sugammadex Rejection?
- Yet another setback for Schering-Plough seems to have taken top management by surprise. Schering’s shares slid nearly four percent by midafternoon on the news that its sugammadex anesthesia-recovery drug would not be approved by the FDA. In a statement, Schering VP Thomas Koestler said he was “surprised...
- Blog posts 2008-08-01
- GSK Roiled by Layoffs: 350 R&D Staff Cut; Scientists in Italy Stage a Strike
- Confusion continues at GlaxoSmithKline this morning as R&D employees attempt to figure out if they'll be receiving pink slips and their bosses attempt to keep everyone calm. Tension at the company has been building since Chemistry World reported that GSK sought hundreds of job cuts internationally at...
- Blog posts 2008-08-05
- Is Pfizer's Sleeping Pill Obsession Running up King Stock?
- Trading in options on King Pharmaceuticals shares reached a four-year frenzy yesterday, Reuters reported, and King shares rose to an 11-month high on rumors that Pfizer may be interested in acquiring it. Pfizer pfollowers know that CEO Jeff Kindler made a lot of noise a few years...
- Blog posts 2008-08-06
- As "Superbugs" Rise, Companies Abandon Antibiotic Research
- This week's must-read is Jerome Groopman's article on super-resistant bacteria in the New Yorker. If you get infected, the bacteria destroy your lungs and you end up drowning in your own blood. There's no cure: Antibiotics no longer work against them. These bugs are "literally resistant to...
- Blog posts 2008-08-07
- GSK and Others See Massachusetts Showdown Over Drug-Marketing Reform
- There are two ideas floating in the world of politics to curb the way drug companies give doctors gifts and often biased information. One of them is a good idea, and one of them is a bad idea. Drug companies -- such as GlaxoSmithKline -- have chosen...
- Blog posts 2008-08-08
- GSK's Alli Diet Drug Has Problems With Your "Fat Friend"
- The official blog of GlaxoSmithKline's Alli diet drug franchise has suddenly adopted a decidedly different voice. Alliconnect used to be a series of posts about health, nutrition, and some upfront warnings about Alli's side effects eat too much fatty food and you can lose bowel control. It...
- Blog posts 2008-08-11
- It’s Good News, Bad News for Gilead’s HIV Pill
- The good news: The FDA approved Viread, Gilead’s dwindling HIV treatment, as a therapy for hepatitis B. The drug’s sales had gone down to $613 million from a peak of $783 million as newer combination drugs -- including Gilead’s own Atripla, which includes Viread -- eroded the market for standalone...
- Blog posts 2008-08-12
- At Sepracor, a Cost-Cutting Exercise Proves Expensive
- Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately 300 sales force positions." The company said it needed to make the layoffs because, by last October, its revenues were falling....
- Blog posts 2008-08-13
- Not Everyone Thinks Pharma's Legal Liabilities Are Impossible to Calculate
- Few things are less sexy than proposed changes in accounting rules for drug companies, but bear with me -- this is actually interesting. Lilly, Johnson & Johnson, Merck, Novartis, Pfizer and Wyeth have complained about a rule change that would require them to estimate how large their...
- Blog posts 2008-08-14
- Vultures Circle Dendreon Even Though Jury Is Still Out on Provenge
- Dendreon had better pull something amazing out of the hat when it gets the results of its "Impact" study on Provenge, the drug it's developing for prostate cancer -- because investors are already guessing that the results are not going to be good. Back in March, Dendreon...
- Blog posts 2008-08-15
- Body Count Linked to GSK Vaccine Trial Rises
- Fourteen children have now died during a pneumonia vaccine trial run by GlaxoSmithKline in Argentina, according to the U.K.'s Daily Mail. Argentine authorities are investigating. GSK says the deaths are not linked to the tests. This issue first emerged for GSK in July, when TradingMarkets.com reported that...
- Blog posts 2008-08-18
- Pharma Election Money Backs Obama
- After years of funneling campaign money to Republican politicians, the drug business has suddenly decided that the Democrats -- who took control of Congress in the 2006 elections -- will win the White House in the fall. From 1990 until just last year, pharma political campaign contribution...
- Blog posts 2008-08-19
- A Worst-Case Scenario in the Roche-Genentech Bid
- It’s been nearly a month since Roche bid $44 billion to completely buy out Genentech, which seems like a good point at which to ask whether Roche, if successful, could end up destroying the value it’s seeking to acquire. When the bid was announced, there were immediate...
- Blog posts 2008-08-20
- As Roche Looks on, Genentech's Big Avastin Study Attracts Critics
- A handful of scientists are skeptical that Genentech’s C-08 trial of its Avastin anti-cancer drug will show any benefit in preventing the recurrence of colorectal cancer following surgery, reports PharmaWire via the Financial Times. Avastin is one of Genentech's most valuable products, and currently rakes in sales...
- Blog posts 2008-08-21
- Noven and P&G Try "Viagra for Women" Despite History of Failure
- Yet another company is taking a crack at the "Viagra for women" concept. This time it is Noven Pharmaceuticals, which has licensed its testosterone-based skin patch to Procter & Gamble. The companies did not disclose the terms of the deal. The move is an interesting one for...
- Blog posts 2008-08-22
- What Lilly Learned From Steak n Shake: A Q&A on Cymbalta
- Eli Lilly’s Cymbalta is fast adding indications. Today the company announced the results of a trial to see if the drug can be used for back pain and last week it was approved in Europe for generalized anxiety disorder. Its wide variety of uses --...
- Blog posts 2008-08-25
- Abbott Labs' "Position of Strength" May Not Be as Strong as It Looks
- Figuring out whether Abbott Laboratories is firing on all cylinders or heading for a wall is a complicated business. On the one hand, the company announced it would lay off 1,000 employees in its diagnostics business. Abbott spokesperson Melissa Brotz said: We are taking this action...
- Blog posts 2008-08-26
- << Previous
- page 1 of 80
- Next >>
Refining Tags
- Marketing (349 results)
- Finance (323 results)
- Advertisement (314 results)
- Human Resources (236 results)
- Business Operations (189 results)
- Advertising & Promotion (188 results)
- Government (167 results)
- Sales (163 results)
- Pfizer Inc. (161 results)
- Sales Strategy (151 results)
- Investment (136 results)
- Federal Government (136 results)
- Agency (135 results)
- Workforce Management (112 results)
- Operational Accounting (106 results)
- Sales Force Management (105 results)
- FDA (97 results)
- Benefits (88 results)
- Layoff (84 results)
- Financial Accounting (79 results)
- Revenue (76 results)
- Healthcare (76 results)
- Corporate Law (70 results)
- Internet (69 results)
- Litigation (66 results)
- Mergers & Acquisitions (64 results)
- CEO (58 results)
- Marketing Research (57 results)
- Corporate Communications (54 results)
- Vertical Industries (53 results)
- Management (51 results)
- Job (49 results)
- Branding (49 results)
- Merck & Co. Inc. (49 results)
- Bayer AG (48 results)
- Johnson & Johnson (47 results)
- Personal Finance (46 results)
- WPP (45 results)
- Recruitment & Selection (45 results)
- Corporate Governance (42 results)
- Financial Planning (40 results)
- Software (40 results)
- Gender And Diversity (39 results)
- Stock (38 results)
- AstraZeneca Plc. (38 results)
- Wyeth (37 results)
- Enterprise Software (36 results)
- Blogging (35 results)
- Pharmaceutical Company (35 results)
- Personal Technology (34 results)
